| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. |
| 掲載誌名 | 正式名：Lung cancer (Amsterdam, Netherlands) 略 称：Lung Cancer ISSNコード：18728332/01695002 |
| 巻・号・頁 | 214,pp.109305 |
| 著者・共著者 | Hidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, Se-Hoon Lee, Pongwut Danchaivijitr, Adlinda Alip, Hailin Xiong, Soon-Hin How, Gee-Chen Chang, James Chih-Hsin Yang, Yuta Yamanaka, Mehmet Ali Nahit Şendur, Kumar Prabhash, Koichi Azuma, Alianu Akawung, Elizabeth Fennema, Xiaodan Tang, Sujay Shah, Seema Sethi, Shun Lu |
| 発行年月 | 2026/02 |
| 概要 | BACKGROUND:Approximately 60 % of lung cancer cases occur in Asia, indicating an epidemiological disparity and need for effective therapies. Amivantamab-lazertinib is approved for first-line EGFR-mutated advanced non-small cell lung cancer (NSCLC) in many countries. In the protocol-specified final overall survival (OS) analysis of MARIPOSA (NCT04487080), amivantamab-lazertinib showed a statistically significant and clinically meaningful improvement in OS versus osimertinib (HR, 0.75; P = 0.005) among all participants. We evaluated OS for amivantamab-lazertinib versus osimertinib in Asian participants.PATIENTS AND METHODS:Participants with previously untreated EGFR-mutated, locally advanced/metastatic NSCLC were randomized 2:2:1 to receive amivantamab-lazertinib, osimertinib, or lazertinib (for evaluating contribution of components). Self-identified Asian race was a stratification factor. OS was a key secondary endpoint.RESULTS:Of 1074 randomized participants, 629 self-identified as Asian (amivantamab-lazertinib:250; osimertinib:251; lazertinib:128). At a median follow-up of 38.7 months, amivantamab-lazertinib significantly prolonged OS versus osimertinib among Asian participants. Median OS was not reached (NR; 95 % CI, NR-NR) for amivantamab-lazertinib versus 38.4 months (95 % CI, 35.1-NR) for osimertinib (HR, 0.74; 95 % CI, 0.56-0.97; nominal P = 0.026). Assuming exponential distribution of OS in both arms, amivantamab-lazertinib is projected to prolong median OS among Asian participants by > 12 months versus osimertinib. At 36 months, 61 % and 53 % were alive in the amivantamab-lazertinib and osimertinib arms. Safety profile was consistent with the overall population.CONCLUSIONS:Consistent with the overall population, amivantamab-lazertinib significantly improved OS versus osimertinib among Asian participants with previously untreated EGFR-mutated advanced NSCLC, making it the first regimen to improve survival among Asian patients. |
| DOI | 10.1016/j.lungcan.2026.109305 |
| PMID | 41689889 |